A Study of LY4515100 in Healthy Male Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Eli Lilly and Company
Study ID
NCT07867327
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • [¹⁴C]-LY4515100 Oral Solution — DRUG
    \[¹⁴C\]-LY4515100 administered orally
  • LY4515100 Tablet — DRUG
    LY4515100 administered orally
  • [¹⁴C]-LY4515100 IV — DRUG
    \[¹⁴C\]-LY4515100 administered IV

Study Details

The main purpose of this study is to evaluate how the body handles \[¹⁴C\]-LY4515100. The study will investigate how much \[¹⁴C\]-LY4515100 enters the bloodstream from the stomach or intestines and is available to have an effect on the body, how the body changes \[¹⁴C\]-LY4515100 so that it can be used or removed, and how the body gets rid of \[¹⁴C\]-LY4515100. For each participant, the study will last about 9 weeks and will include a Clinical Research Unit (CRU) stay lasting between 10 and 30 days.

Key Dates

First listed
Oct 9, 2026
Start date
Oct 31, 2026
Status verified
Oct 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
16 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: [¹⁴C]-LY4515100 Part 1
    \[¹⁴C\]-LY4515100 containing radioactivity administered orally
  • Experimental: LY4515100 + [¹⁴C]-LY4515100 Part 2
    LY4515100 administered orally with \[¹⁴C\]-LY4515100 containing radioactivity administered intravenously (IV)

Primary Outcome Measure

Part 1: Urinary Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [ Time Frame: Predose Up to Day 14 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitMadisonWisconsin53704
608-442-8200
Kimberly Cruz (PRINCIPAL_INVESTIGATOR)

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit· Madison, WI

Related Studies